Market Overview:
Ivermectin is a macrocyclic lactone antibiotic that is used to treat a variety of parasitic infections. It is also effective in the treatment of onchocerciasis, head lice, and other parasites. Ivermectin for human market by type (topical (cream and lotion), oral, injection), by application (for onchocerciasis treatment, for head lice treatment, others) and region (north America, latin america, europe, asia pacific and middle east & africa) is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of parasitic infections across the globe coupled with rising awareness about available treatments options.
Product Definition:
Ivermectin is a prescription drug used to treat certain infections caused by parasites, including head lice, scabies, and river blindness. It is also used to control some types of worm infections. Ivermectin belongs to a class of drugs called macrocyclic lactones. It works by killing the parasites or worms.
Topical (Cream and Lotion):
Ivermectin is a topical cream or lotion used for the treatment of scabies. Scabies is a parasitic infection that affects the skin. The most common symptom associated with it is itchy skin, which may lead to severe scratching and sometimes marks behind the ears, arms, legs or other parts of the body. Ivermectin works by killing mites that are causing itchiness through an anti-coagulant effect on their blood vessels.
Oral:
Oral is a form of drug delivery systems that involves the administration of drugs in the form of tablets or capsules. The drug is administered by mouth, either with or without food. It can be used for various indications such as parasitic infections, gynecological disorders and other diseases caused due to bacteria and viruses. Ivermectin is an oral medication used for treating heartworm disease in animals as well as humans.
Application Insights:
On the basis of application, the global ivermectin for human market is segmented into onchocerciasis treatment, headlice treatment, others. Onchocerciasis is a tropical disease that affects people living in rural areas of Africa and Latin America. The World Health Organization (WHO) estimates that approximately 36 million people are affected by onchocerciasis worldwide. Ivermectin is used to treat this disease as it blocks filarial nematode migration pathway which helps in destroying parasitic worms from the body. Thus increasing demand for ivermectin to treat onchocerciasis will drive growth during forecast years.
Headlice treatment was estimated as largest revenue generating segment owing to increase in prevalence of pediculosis or head lice infestation among children.
Regional Analysis:
North America dominated the market in 2017 owing to the presence of key manufacturers and a high prevalence of head lice. Moreover, increasing awareness about ivermectin-based treatment for onchocerciasis is expected to drive regional growth over the forecast period. The U.S., in particular, is one of the most affected countries with regard to river blindness and onchocerciasis; therefore, continuous efforts are being undertaken by various organizations in order to increase awareness regarding these conditions and spread information related to available treatments are expected contribute towards market growth during the forecast period.
Asia Pacific region is anticipated witness significant growth over the coming years due as oral ivermectin products have gained approval from regulatory agencies such as China Food.
Growth Factors:
- Increasing prevalence of parasitic infections: The increasing prevalence of parasitic infections is one of the major growth drivers for the global ivermectin market. According to a study by the World Health Organization (WHO), there are more than 1 billion people who are infected with parasites, and this number is estimated to increase in the coming years. This will create a high demand for ivermectin, as it is one of the most effective drugs against parasitic infections.
- Rising awareness about neglected tropical diseases: There is a growing awareness among people about neglected tropical diseases (NTDs), such as river blindness and elephantiasis, which are caused by parasites. This has led to an increase in demand for ivermectin, as it is an effective drug against these diseases.
- Growing population: The world’s population is growing at a rapid pace and this will lead to an increased incidence of parasitic infections worldwide. This will create a high demand for ivermectin, as it is one of the most effective drugs against these infections..
Scope Of The Report
Report Attributes
Report Details
Report Title
Ivermectin for Human Market Research Report
By Type
Topical (Cream and Lotion), Oral, Injection
By Application
For Onchocerciasis Treatment, For Headlice Treatment, Others
By Companies
Merck, Perrigo Company plc, Arbor Pharms LLC, TARO, Edenbridge Pharms, TEVA Pharms USA, Wellona Pharma, Galderma Laboratories LP, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
167
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Ivermectin for Human Market Report Segments:
The global Ivermectin for Human market is segmented on the basis of:
Types
Topical (Cream and Lotion), Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
For Onchocerciasis Treatment, For Headlice Treatment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Perrigo Company plc
- Arbor Pharms LLC
- TARO
- Edenbridge Pharms
- TEVA Pharms USA
- Wellona Pharma
- Galderma Laboratories LP
- Merck
Highlights of The Ivermectin for Human Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Topical (Cream and Lotion)
- Oral
- Injection
- By Application:
- For Onchocerciasis Treatment
- For Headlice Treatment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ivermectin for Human Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ivermectin is a medication used to treat infections caused by parasites. It works by killing the parasites. Ivermectin is also used to prevent the spread of infection in people who are infected with malaria.
Some of the major companies in the ivermectin for human market are Merck, Perrigo Company plc, Arbor Pharms LLC, TARO, Edenbridge Pharms, TEVA Pharms USA, Wellona Pharma, Galderma Laboratories LP, Merck.
The ivermectin for human market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ivermectin for Human Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ivermectin for Human Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ivermectin for Human Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ivermectin for Human Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ivermectin for Human Market Size & Forecast, 2018-2028
4.5.1 Ivermectin for Human Market Size and Y-o-Y Growth
4.5.2 Ivermectin for Human Market Absolute $ Opportunity
Chapter 5 Global Ivermectin for Human Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ivermectin for Human Market Size Forecast by Type
5.2.1 Topical (Cream and Lotion)
5.2.2 Oral
5.2.3 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ivermectin for Human Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ivermectin for Human Market Size Forecast by Applications
6.2.1 For Onchocerciasis Treatment
6.2.2 For Headlice Treatment
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ivermectin for Human Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ivermectin for Human Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ivermectin for Human Analysis and Forecast
9.1 Introduction
9.2 North America Ivermectin for Human Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ivermectin for Human Market Size Forecast by Type
9.6.1 Topical (Cream and Lotion)
9.6.2 Oral
9.6.3 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ivermectin for Human Market Size Forecast by Applications
9.10.1 For Onchocerciasis Treatment
9.10.2 For Headlice Treatment
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ivermectin for Human Analysis and Forecast
10.1 Introduction
10.2 Europe Ivermectin for Human Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ivermectin for Human Market Size Forecast by Type
10.6.1 Topical (Cream and Lotion)
10.6.2 Oral
10.6.3 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ivermectin for Human Market Size Forecast by Applications
10.10.1 For Onchocerciasis Treatment
10.10.2 For Headlice Treatment
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ivermectin for Human Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ivermectin for Human Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ivermectin for Human Market Size Forecast by Type
11.6.1 Topical (Cream and Lotion)
11.6.2 Oral
11.6.3 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ivermectin for Human Market Size Forecast by Applications
11.10.1 For Onchocerciasis Treatment
11.10.2 For Headlice Treatment
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ivermectin for Human Analysis and Forecast
12.1 Introduction
12.2 Latin America Ivermectin for Human Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ivermectin for Human Market Size Forecast by Type
12.6.1 Topical (Cream and Lotion)
12.6.2 Oral
12.6.3 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ivermectin for Human Market Size Forecast by Applications
12.10.1 For Onchocerciasis Treatment
12.10.2 For Headlice Treatment
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ivermectin for Human Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ivermectin for Human Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ivermectin for Human Market Size Forecast by Type
13.6.1 Topical (Cream and Lotion)
13.6.2 Oral
13.6.3 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ivermectin for Human Market Size Forecast by Applications
13.10.1 For Onchocerciasis Treatment
13.10.2 For Headlice Treatment
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ivermectin for Human Market: Competitive Dashboard
14.2 Global Ivermectin for Human Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Perrigo Company plc
14.3.3 Arbor Pharms LLC
14.3.4 TARO
14.3.5 Edenbridge Pharms
14.3.6 TEVA Pharms USA
14.3.7 Wellona Pharma
14.3.8 Galderma Laboratories LP
14.3.9 Merck
